敏感结核病治疗：从24个月到2个月

doi:10.3969/j.issn.1006-5725.2023.19.001

Abstract

Abstract:

The results of a clinical trial using an 8?week combination regimen of new drugs to treat sensitive tuberculosis， published by The New England Journal of Medicine in March 2023， have raised new expectations for further shortening the course of treatment for sensitive tuberculosis. Whether the treatment of sensitive TB must follow the standard 6-month chemotherapy regimen？ This article reviews the historical evolution of the treatment plan for sensitive tuberculosis，and Propose thoughts and prospects for future treatment directions based on the current situation in China。

Key words: tuberculosis, sensitive tuberculosis, drug?resistant tuberculosis, standardized treatment, short?coruse therapy

CLC Number:

Liang LI,Yuhong. LIU. Treatment course of sensitive tuberculosis： From 24 months to 2 months[J]. The Journal of Practical Medicine, 2023, 39(19): 2421-2423.

References 14

1	BAGCCHI S. Global tuberculosis report 2022［J］. Lancet Microbe， 2023，4（1）：e20
2	WHO consolidated guidelines on tuberculosis： module 4： treatment： drug-susceptible tuberculosis treatment［EB/OL］. Geneva： World Health Organization， 2022.
3	PATON N I， COUSINS C， SURESH C，et al. Treatment strategy for rifampin-susceptible tuberculosis［J］. N Engl J Med， 2023， 388（10）：873-887.
4	Streptomycin treatment of pulmonary tuberculosis， a medical research council investigation［J］. Br Med J，1948，2（4582）：769-782
5	World Health Organization tuberculosis program for 1950［J］. Public Health Rep，1949，64（35）：1117-1123.
6	Second East African/British Medical Research Council Study. Controlled clinical trial of four 6-month regimens of chemotherapy for pulmonary tuberculosis. Second report［J］. Am Rev Respir Dis， 1976， 114（4）：471-475.
7	HART P D. Chemotherapy of tuberculosis； research during the past 100years［J］. Br Med J，1946，2（4482）：805-810.
8	World Health Organization. Global tuberculosis report 2021［EB/OL］. Geneva： World Health Organization，2021.
9	Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis［J］. Am Rev Respir Dis， 1979， 119（4）：579-585.
10	Long-term follow-up of a clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council［J］. Am Rev Respir Dis， 1986，133（5）：779-783.
11	Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis： the results up to 30 months［J］. Tubercle， 1981， 62（2）：95-102.
12	A controlled clinical trial of oral short-course regimens in the treatment of sputum positive pulmonary tuberculosis. Tuberculosis Research Centre［J］. Int J Tuberc Lung Dis 1997， 1（6）：509-517.
13	GILLESPIE S H， CROOK A M， MCHUGH T D，et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis［J］. N Engl J Med， 2014，371（17）：1577–1587.
14	DORMAN S E， NAHID P， KURBATOVA E V，et al. Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis［J］. N Engl J Med， 2021，384（18）：1705-1718.

[1]	Qi CHEN,Yaxi ZHANG,Mingxia ZHANG,Jieyun ZHANG,Qianting. YANG. The detection value of tuberculosis-specific QFT-TB in different types of specimens of tuberculosis patients [J]. The Journal of Practical Medicine, 2024, 40(7): 1002-1005.
[2]	Xiaotong LIU,Xianhua SU,Zhijun XIN,Fengqiong GAO,Jiayi FENG,Tongxia. XIA. Risk factors of postoperative complications in patients with spinal tuberculosis and the predictive value of prognostic nutritional index [J]. The Journal of Practical Medicine, 2024, 40(7): 972-978.
[3]	Wenji ZHUO,Ran WEI,Yanmei CHEN,Xunxun CHEN,Meiling YU,Huixin GUO,Hongdi LIANG,Jing LIANG,Xiaoyu. LAI. Drug resistance characteristics and treatment strategies of TB patients in three age groups in Guangdong Province from 2014 to 2020 [J]. The Journal of Practical Medicine, 2024, 40(5): 702-707.
[4]	Yigang TAN,Haobin KUANG,Hongmei FU,Chunyan LI,Xiaobing ZHAO,Lijing XUE. Analysis of clinical characteristics of 33 cases of tuberculosis complicated by tumor necrosis factor⁃α inhibitor in autoimmune diseases [J]. The Journal of Practical Medicine, 2024, 40(3): 378-383.
[5]	Linlin GAI,Weice SUN,Jinjin CHU,Donghua XU. Changes of M1/M2 macrophages polarization associated with active pulmonary tuberculosis and the effect of ESAT6 on macrophage polarization [J]. The Journal of Practical Medicine, 2024, 40(20): 2867-2873.
[6]	Haojie TANG,Zilong YANG,Zhaoxian YU,Zhiyu FENG,Haiping DONG,Xiang LI,Wei ZHAO,Haobin. KUANG. Construction and evaluation of a risk prediction model for linezolid-related neurological adverse reactions in patients with multidrug-resistant tuberculosis [J]. The Journal of Practical Medicine, 2024, 40(19): 2690-2695.
[7]	Shuyu ZHANG,Yuehong. LI. An overview of mycobacterium tuberculosis infection after kidney transplantation [J]. The Journal of Practical Medicine, 2024, 40(15): 2047-2050.
[8]	Yigang TAN,Honglan ZHONG,Chunming LUO,Xingshan CAI,Bitong WU,Hui FAN,Min. SONG. Clinical analysis of pulmonary tuberculosis complicated with Nocardia farcinica [J]. The Journal of Practical Medicine, 2024, 40(14): 1969-1974.
[9]	Jing GUI,Feng WANG,Hui YANG,Yumao CAI,Chuangyue. HONG. Investigation of oxidised low⁃density lipoprotein as a risk assessment indicator in patients with type 2 diabetes mellitus combined with pulmonary tuberculosis [J]. The Journal of Practical Medicine, 2024, 40(14): 1995-2002.
[10]	Wendi ZHOU,Jiamin LIN,Daichen JU,Qi WANG,Jialou ZHU,Ning SU,Jinxing. HU. Proteomic profiling and functional analysis of differentially expressed proteins in lung cancer coexistent with pulmonary tuberculosis [J]. The Journal of Practical Medicine, 2024, 40(13): 1814-1821.
[11]	Shengming YU,Lianghua XIA,Jiahuan ZHAN,Siqi LIU,Wei WANG,Liang YAN,Kaisen. CHEN. Study on the mutation characteristics of streptomycin genes of Multidrug-Resistant Mycobacterium Tuberculosis in Jiangxi Province [J]. The Journal of Practical Medicine, 2024, 40(1): 91-96.
[12]	Gang LIU,Rushu LAN,Huifang QIN,Xiaoling QIN,Yixiang QIN,Ruolan XU,Dan. LUO. Mutation characteristics of ethambutol resistance gene of Mycobacterium tuberculosis in Guangxi [J]. The Journal of Practical Medicine, 2023, 39(24): 3261-3266.
[13]	Nenhan WANG,Yanfeng ZHAO,Lili TIAN,Shuangshuang CHEN,Hao CHEN,Yixuan REN,Chuanyou LI,Xiaowei. DAI. Clinical application of fluorescence polymerase chain reaction probe melting curve technique in detecting isoniazid drug⁃resistance of Mycobacterium tuberculosis in sputum samples [J]. The Journal of Practical Medicine, 2023, 39(20): 2664-2670.
[14]	FU Xuefeng, LOU Siyu, PENG Zhangli.. Mycobacterium tuberculosis Rv3737 suppresses macrophage autophagy to enhance bacterial survival in macrophages [J]. The Journal of Practical Medicine, 2023, 39(2): 198-203.
[15]	LIU Zhenning, XU Yunyi, HU Lihuan, LIU Zhihui, HU Jinxing, LI Hua, GUAN Ping.. The clinical value of peripheral blood cell analysis and tuberculosis antibody detection in the diagnosis of pulmonary tuberculosis [J]. The Journal of Practical Medicine, 2023, 39(2): 262-266.

Treatment course of sensitive tuberculosis： From 24 months to 2 months

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 14

Related Articles 15

Recommended Articles

Metrics

Comments